Cotellic (cobimetinib) — United Healthcare

Initial criteria

• Diagnosis of one of the following histiocytic neoplasms: Langerhans cell histiocytosis or Erdheim-Chester disease

Reauthorization criteria

• Patient does not show evidence of progressive disease while on Cotellic therapy

Approval duration

12 months